RecruitingPhase 1NCT06884098

A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284

An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-228B with AD-2284 in Healthy Adult Volunteers

Sponsor

Addpharma Inc.

Enrollment

60 participants

Start Date

Mar 10, 2025

Study Type

INTERVENTIONAL

Conditions

Primary Hypercholesterolaemia

Summary

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AD-2284 and a drug called AD-228B for people with primary hypercholesterolaemia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAD-228B

AD-228B, 1Tab., Per Oral

DRUGAD-2284

AD-2284, 1Tab., Per Oral

Locations(1)

H Plus Yangji Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06884098